Literature DB >> 27266832

Long-term progress of six cases of malignant peripheral nerve sheath tumors of the mediastinum that underwent surgical treatment: Case report series.

Yuki Nakajima1, Iwao Mikami2, Hirohiko Akiyama2, Hiroyasu Kinoshita2, Yoshihito Iijima2, Hidetaka Uramoto2.   

Abstract

INTRODUCTION: Malignant Peripheral Nerve Sheath Tumor is a rare type of soft tissue malignant tumor that occurs in only 5% of cases. It tends to occur in the arms and legs and trunk of the body, with mediastinal occurrence in only a few cases. Among mediastinal tumors, only 18.8% occur primarily in the nerves, and of these, only 10.3% are malignant, with very few reports indicating the long-term progress of patients with MPNST of the mediastinum. CASE
PRESENTATION: We studied six cases of mediastinal primary malignant peripheral nerve sheath tumors in which surgery was carried out at this Center between 1977 and 2000. Four of the cases were men and two were women. The period of observation was between 14 and 277 months and the median follow-up time was 119.5 months. The tumors were contained in a membrane and completely excisable in three cases, with the patient demonstrating long-term survival with no recurrence in each case. The remaining three cases were not completely excisable due to invasion into the aorta. In two cases, the patients were treated post-surgically with chemotherapy; however, in all three cases the patient died as a result of the original condition. DISCUSSION AND
CONCLUSIONS: Nerve sheath tumors localized within the membrane offer good long-term prognosis even if malignant. Furthermore, long-term survival is possible even if the tumor has invaded neighboring organs, provided it can be completely excised. In cases where complete excision is difficult, a multidisciplinary approach including radiotherapy and anti-cancer drug treatment may contribute to improved prognosis but this is a subject that requires further study.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  MPNST; Malignant peripheral nerve sheath tumor; Malignant schwannoma; Mediastinal tumor; Surgery

Year:  2016        PMID: 27266832      PMCID: PMC4908608          DOI: 10.1016/j.ijscr.2016.05.006

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


Introduction

Malignant Peripheral Nerve Sheath Tumor (MPNST) is a rare type of soft tissue malignant tumor that occurs in only 5% of cases [1]. It tends to occur in the arms and legs and trunk of the body, with mediastinal occurrence in only a few cases [1]. Among mediastinal tumors, only 18.8% occur primarily in the nerves, and of these, only 10.3% are malignant, with very few reports indicating the long-term progress of patients with MPNST of the mediastinum [2]. In this study, the authors considered the long-term surgical results of six cases of MPNST treated surgically at this hospital.

Presentation of cases

We studied the long-term progress of six patients undergoing surgery at this Center between 1977 and 2000 for mediastinal primary malignant peripheral nerve sheath tumors. Four of the patients were men and two were women. Their ages ranged from 17 to 72 years (averaging 51 years). The primary location was the anterior mediastinum in three cases, middle mediastinum in one case and superior mediastinum in two cases. The tumor diameter was between 70 and 150 mm (average 101.8 mm). (Table 1) The period of observation was between 14 and 277 months and the median follow-up time was 119.5 months. None of the cases had a diagnosis prior to surgery; however, swift diagnosis during surgery led to suspicion of a malignant nerve sheath tumor. In three of the six cases (Cases 2, 4 and 5) the tumor was enclosed in a membrane, with no invasion of the surrounding area, enabling complete excision thereof (Fig. 1). Cases 2 and 4 were treated with surgery alone, while Case 5 went on to undergo radiotherapy. All three of these cases went on to have long-term survival of ten years or more with no recurrence. The remaining three cases (Cases 1, 3 and 6) involved invasion into the aorta and could not be completely excised. In Case 6, the lung and aorta were also excised, but surgical margins were positive. In Cases 1 and 3, the patients were post-surgically treated with chemoradiotherapy, but in Case 6, no further treatment was carried out because of the poor physical state of the patient. All three of these patients died from the original condition (Table 2).
Table 1

Mediastinal MPNST:characteristics.

CaseAgeSexSymptomsLocationSize(mm)Preoperative diagnosis
117MBack pain, CoughP150Neurogenic tumor
265MS75Mediastinal tumor
350MBack painP70Neurogenic tumor
445FChest oppression, CoughM86Lung tumor
555FS110Mediastinal tumor
672MBack painP120Schwannoma

P: posterior mediastinum, S: superior mediastinum, M, middle mediastinum.

Fig. 1

(A) Intraoperative image of case 4. The tumor originated from the vagus nerve. (B) Intraoperative image of case 4. The tumor could be smoothly detached from the aorta.

Table 2

Treatment and outcome.

CaseSurgical approachSurgical treatmentCTRTRecurrenceFollow-up (months)
1PLExtirpation (incomplete)+40Local, brain69, death
2MSExtirpation170, deatha
3PLExploratory thoracotomy+7014, death
4PLExtirpation277, alive
5MSExtirpation46255, alive
6PLExtirpationlocal18, death

CT: Chemotherapy, RT: Radiotherapy, PL: posterolateral, MS: median sternotomy.

Died of other disease.

Discussion

The five-year survival rate for MPNST is between 34 and 43.7%. Localized recurrence after excision is 46–65%, with the distal metastasis rate considered between 40 and 68% [3], [4], [5]. Factors in poor prognosis include: 1. Age at onset of 30 or lower; 2. Large tumor diameter; 3. Occurrence inside the trunk; 4. Complicated by nerve fiber tumor type 1; and 5. Incomplete excision, with the three cases in this study that died having factors 2, 3 and 5 [3], [4], [6]. During treatment of MPNST, it is important to completely surgically excise the tumor. In the cases in this study, the three patients whose tumors were enclosed in a membrane and could be completely excised all survived with no recurrence. Many tumors occur on the surface of the limbs or trunk, allowing them to be discovered early and completely excised; however, those occurring inside the chest or abdomen take longer for the symptoms to express and in many cases discovery is delayed, meaning that the tumor grows and in many cases can no longer be completely excised upon discovery, or may be inoperable. Chemotherapy or radiotherapy has conventionally been implemented on cases in which complete excision cannot be performed, or inoperable cases; however, the results are insufficiently effective. More recently, however, reports note cases in which high dose Ifosfamide, vincristine, doxorubicin, cyclophosphamide have been notably effective, as well as cases in which post-surgery high dose radiation was effective, and those in which boron neutron capture therapy has been effective [7], [8], [9]. In the future, further studies need to be conducted to establish the effectiveness of these therapies. In Case 1 in this study, the patient was post-surgically treated with 60 Gy radiotherapy and cyclophosphamide, along with the anticancer drug cisplatin, which yielded temporary results, achieving survival for 69 months.

Conclusion

This study considered the long-term surgical results in six cases of mediastinally occurring MPNST treated at this hospital. MPNST localized within the membrane, which can be completely excised, offer good long-term prognosis. Furthermore, long-term survival is possible even if the tumor has invaded neighboring organs, providing it can be completely excised. In cases where complete excision is difficult, a multidisciplinary approach including radiotherapy and anti-cancer drug treatment may contribute to improved prognosis but this is a subject that requires further study.

Conflict of interest

The authors report no conflict of interest.

Funding

None.

Consent

Informed and written consent has been given by patients.
  8 in total

1.  Clinical effectiveness of boron neutron capture therapy for a recurrent malignant peripheral nerve sheath tumor in the mediastinum.

Authors:  Masayoshi Inoue; Chun Man Lee; Koji Ono; Minoru Suzuki; Toshiteru Tokunaga; Yoshiki Sawa; Meinoshin Okumura
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

2.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases.

Authors:  B S Ducatman; B W Scheithauer; D G Piepgras; H M Reiman; D M Ilstrup
Journal:  Cancer       Date:  1986-05-15       Impact factor: 6.860

Review 3.  Soft tissue sarcomas.

Authors:  J J Lewis; M F Brennan
Journal:  Curr Probl Surg       Date:  1996-10       Impact factor: 1.909

4.  [Mediastinal tumors--a statistical nationwide report of 1,546 cases between July, 1975 and May, 1979 in Japan (author's transl)].

Authors:  H Wada; T Teramatsu
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1982-03

5.  Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report.

Authors:  K Yone; K Ijiri; K Hayashi; M Yokouchi; T Takenouchi; K Manago; Y Nerome; O Ijichi; N Ikarimoto; S Komiya
Journal:  Spinal Cord       Date:  2004-03       Impact factor: 2.772

6.  Malignant peripheral nerve sheath tumors (malignant schwannomas) in children.

Authors:  J M Meis; F M Enzinger; K L Martz; J A Neal
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

7.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases.

Authors:  J E Wanebo; J M Malik; S R VandenBerg; H J Wanebo; N Driesen; J A Persing
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

8.  A malignant peripheral nerve-sheath tumour responding to chemotherapy.

Authors:  F Masui; R Yokoyama; S Soshi; Y Beppu; K Asanuma; K Fujii
Journal:  J Bone Joint Surg Br       Date:  2004-01
  8 in total
  1 in total

Review 1.  The role of molecular pathology in mediastinal sarcomas.

Authors:  David Ilan Suster
Journal:  Mediastinum       Date:  2020-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.